CONMED Corporation announced its third quarter financial results, highlighting revenue growth compared to the third quarters of 2020 and 2019, despite facing a challenging macro environment. The company is now targeting the lower end of its previously issued full-year 2021 revenue guidance and expects full-year 2021 adjusted diluted net earnings per share to be in the range of $3.18 to $3.23.
CONMED's revenue grew despite a challenging macro environment.
The company is targeting the lower end of its previously issued full-year 2021 revenue guidance.
CONMED expects approximately 100 basis points of foreign exchange headwind to fourth quarter revenue growth.
Full-year 2021 adjusted diluted net earnings per share are expected to be in the range of $3.18 to $3.23.
Given the continued uncertainty related to the global pandemic and the impact on hospitals, the Company is now targeting the lower end of its previously issued full-year 2021 revenue guidance of $1.015 billion to $1.035 billion. Based on recent exchange rates, the Company expects approximately 100 basis points of foreign exchange headwind to fourth quarter revenue growth. The Company now expects full-year 2021 adjusted diluted net earnings per share in the range of $3.18 to $3.23, compared to its prior range of $3.15 to $3.25.